Biosynex

Biosynex SA, established in 2005 by Larry Abensur, Thierry Paper, and Thomas Lamy, operates in the in-vitro diagnostics market, focusing on the design, manufacture, and distribution of rapid diagnostic tests (RDTs). The company is headquartered in Illkirch-Graffenstaden, France, within the Alsace region. Abensur, with his background as a pharmacist, along with his co-founders, identified a need for faster and more accessible diagnostic tools, steering the company's direction from its inception. Biosynex has strategically grown through a combination of organic development and targeted acquisitions, such as the 2020 acquisition of the Swiss company, Medipharm, and the American company, ProciseDx, in 2023, expanding its product portfolio and geographical reach.

The company's business model is centered on providing rapid testing solutions to a diverse client base that includes pharmacies, medical analysis laboratories, hospitals, and public health organizations. Its revenue is generated through the sale of these diagnostic products. The product line is extensive, covering various health areas. For professional use, Biosynex offers tests for infectious diseases like influenza, COVID-19, and strep A, as well as markers for cardiology and oncology. A significant part of their strategy involves making diagnostics more accessible to the general public through self-tests available in pharmacies for conditions such as pregnancy, HIV, and various infections. This dual approach, serving both healthcare professionals and consumers, allows Biosynex to capture a broad segment of the diagnostics market.

The core of Biosynex's offering is its range of rapid diagnostic tests, which deliver results quickly, often within minutes, at the point of care. For instance, their COVID-19 antigen and antibody tests became crucial during the global pandemic. Beyond infectious diseases, the company has developed the AMPLIQUICK® range for molecular biology and offers point-of-care (POC) instruments that provide quantitative measurements for various biological markers, enhancing the capabilities of healthcare providers outside traditional laboratory settings. The acquisition of ProciseDx brought in five CE-marked quantitative tests for therapeutic drug monitoring, further strengthening its position in the point-of-care diagnostics space.

Keywords: rapid diagnostic tests, in-vitro diagnostics, point-of-care, self-testing, medical devices, infectious diseases, diagnostics manufacturing, healthcare solutions, public health, molecular biology